Dave Fornell, DAIC Editor

Dave Fornell, editor of DAIC Magazine

Blog | Dave Fornell, DAIC Editor | Heart Valve Technology| April 05, 2016

Wow! — My Single Word Summary of TAVR Data at ACC 2016

TAVR, Sapien 3, ACC.16

There has been a lot of conjecture that transcatheter aortic valve replacement (TAVR) may one day replace open-heart surgical aortic valve replacement (SAVR). However, after attending the American College of Cardiology (ACC) 2016 meeting, it is evident that change will come much sooner than anyone anticipated. “Wow” is really the key summary I can offer regarding the TAVR vs. SAVR data presented at ACC. Three key presentations were all positive for TAVR, showing it is at least equal or superior to surgery. This is not bad for a new technology with largely inexperienced operators being able to perform as well or better than cardiac surgeons with decades of experience.

The Partner 2A trial for the Sapien XT showed that the second-generation TAVR device was equal to surgery in intermediate-risk surgical patients. It was pointed out by experts in numerous ACC sessions that if the two techniques are equal, the minimally invasive method will usually win out as a new standard of care. 

The improved Sapien 3 device replaced the XT toward the end of the Partner 2 trial. The valve has a fabric skirt that significantly reduces paravalvular leak, which was an issue with the earlier XT and the original versions of the Sapien. The PARTNER results were separated for the XT and Sapien 3 arms of the study. The data for Sapien 3 show it performed better than surgery in intermediate patients. 

Watch a video interview with Vinod Thourani, M.D on the Sapien 3 beating surgery.

U.S. CoreValve pivotal trial results showed TAVR was better than surgery, and the three-year results presented at ACC show a continued positive trend. The lines between TAVR and surgery for all-cause mortality also continue to diverge in favor of TAVR. 

Watch a video interview with Michael Reardon, M.D., co-principal investigator for the CoreValve trial.

Stoke rate have been high with TAVR compared to surgery in earlier trials, but that rate has dropped in recent trials presented at ACC.16 to now be equal with surgery. 

Watch a video interview with Chandan Devireddy, M.D. at ACC.16 explaining the drop in TAVR stroke rates. 

Cardiothoracic surgeon Steven Bolling, M.D., University of Michigan, said TAVR is a brand new technology being implanted by new, inexperienced operators. But, within five years of the technology gaining U.S. market approval, it has beaten out the performance of very specialized, experienced surgeons. He noted that new interventional cardiology operators were able to show better patient outcomes with TAVR than his own surgical outcomes, and he has the experience of performing more than 5,000 surgical valve procedures. Bolling said if a test between two competing technologies shows them to be at least equal, the easiest one to use will always be the ultimate winner. He said there is little doubt in his mind that TAVR will become the standard of care in the next few years.

The three main questions standing in the way of full acceptance of TAVR as a new standard of care are: 1. How it performs in low-risk patients; 2. Durability; and 3. Its ability to gain reimbursement. The U.S. Food and Drug Administration (FDA) gave the green light earlier this year for low-risk patient trials for both the CoreValve and Sapien 3. The results of those trials in a couple years will be very highly anticipated. The long-term durability of TAVR valves will also be assessed in these patients over the next decade.  

Long-term durability data has been hard to track in the extreme- and high-risk patients included in the early PARTNER and CoreValve trials due to high mortality rates. So, this data is expected from the intermediate- and low-risk patient studies, but this will require seven to 10 years of data before a clear picture of durability emerges. 

Reimbursement is still an issue, especially with the average cost of TAVR being several thousand dollars more than surgery. However, the cost of the devices and of the procedures will go down as TAVR’s usage expands, the experts say, as with any new technology. The current cost-conscious healthcare environment will also likely embrace TAVR as the cost drops, especially as this minimally invasive technique increasingly becomes a same-day outpatient procedure.

Related Content

American College of Cardiology Names Douglas Drachman Next Annual Scientific Session Vice Chair

Image courtesy of Massachusetts General Hospital

News | ACC | October 08, 2019
Douglas Drachman, M.D., FACC, has been selected as the next vice chair of the American College of Cardiology’s (ACC)...
SyncVision iFR Co-registration from Philips Healthcare maps pressure readings onto angiogram. Results from an international study presented at ACC 2019 indicates pressure readings obtained using iFR (instantaneous wave-free ratio, also referred to as instant wave-free ratio or instant flow reserve) in coronary arteries may localize stenoses that remain after interventions. FFR in the cath lab.

SyncVision iFR Co-registration from Philips Healthcare maps pressure readings onto angiogram. Results from an international study presented at ACC 2019 indicates pressure readings obtained using iFR (instantaneous wave-free ratio, also referred to as instant wave-free ratio or instant flow reserve) in coronary arteries may localize stenoses that remain after interventions.

Feature | ACC | March 27, 2019 | Greg Freiherr, Contributing Editor
The fingerprints of value-added medicine were all over products and works-in-progress on the exhibit floor of the a

The opening late-breaking trial at ACC 2019 is the Apple Heart Study, a large-scale, app-based study to identify atrial fibrillation using a smartwatch. Earlier, smaller trials showed this approach might be used in a population health application to proactively identify AFib patients earlier.

Feature | ACC | March 19, 2019
The American College of Cardiology (ACC) released a list of the late
A patient who received HeartMate III LVAD system at ACC.18. The HeartMate 3 was the topic of of the the key late-breaking trials at #ACC18

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC.18. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at this year's conference.

Feature | ACC | March 27, 2018 | Dave Fornell
There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American Colle
Drug Stops Dangerous Bleeding in Patients Taking Factor Xa Inhibitors


News | ACC | March 22, 2018
March 22, 2018 — The experimental drug...
Videos | ACC | March 21, 2018
DAIC Editor Dave Fornell takes a tour of some of the most interesting new technologies on the expo floor at
ACC 2018 Late-Breaking Trials Announced
News | ACC | March 21, 2018
Here is a list of the American College of Cardiology (ACC) 2018 annual meeting late-breaking clinical trials presente
Inhaled Therapy Ineffective in Difficult-to-Treat Heart Failure at ACC 2018.

Image from presentation, "Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF: The INDIE-HFpEF Trial," Borlaug

News | ACC | March 20, 2018
March 20, 2018 — Four weeks of treatment with a novel inhaled medication failed to improve exercise capacity, daily a
More Deaths, Strokes Seen with Perioperative Beta Blocker One Year After Surgery

Image from presentation, "1-Year outcomes of perioperative beta-blockade in patients undergoing noncardiac surgery," Devereaux 

News | ACC | March 20, 2018
March 20, 2018 — During the 12 months after undergoing noncardiac surgery, patients with or at risk for heart disease
Trial for Gout Drug Meets Primary Endpoint, Raises Safety Concerns, image shows a CT scan showing gout in the knees.
News | ACC | March 20, 2018
March 20, 2018 — Febuxostat, a gout dr...
Overlay Init